The newly released guidelines provide a structured, evidence-based, and practical framework for the prevention, early diagnosis, and management of osteoporosis
Pharmed, one of India’s fastest-growing pharmaceutical companies, along with the Indian Orthopaedic Association’s (IOA) Osteoporosis Council recently unveiled the Indian Osteoporosis Guidelines 2025 at IOACON 2025 in Guwahati. The Indian Orthopaedic Association Guidelines for Osteoporosis 2025 have been published in the Indian Journal of Orthopaedics, the official journal of the IOA, underscoring their scientific credibility and national relevance.
The newly released guidelines provide a structured, evidence-based, and practical framework for the prevention, early diagnosis, and management of osteoporosis. They are intended for a wide range of healthcare professionals, including orthopaedic surgeons, physicians, specialists, nurses, and allied healthcare providers involved in osteoporosis care.
Developed using a robust Delphi consensus methodology, the guidelines represent the collective expertise of 62 nationally recognised osteoporosis and bone health experts from across India. The expert panel comprised leading clinicians, researchers, and academicians, including Dr Ramesh Sen, Dr Shiva Shankar Jha, Dr S. S. Amarnath, Dr Jawahar T. Jethwa, Dr Jai Prakash Tiwari, Dr Chinmoy Das, Dr Srinivas Kambhampati, Dr Murali Poduval, Dr Bharatkumar R. Dave, Dr Ram Chaddha, Dr Karthik Vishwanathan, Dr S. Chandrashekara, Dr Renuka Panchagnula, and Dr Sanjay Bhadada, among others.
The development process involved six structured rounds of questionnaires, ensuring scientific rigour, transparency, and alignment with current clinical evidence. This systematic approach ensures that the guidelines reflect current best practices and expert consensus, while remaining adaptable to evolving scientific knowledge over the next five to six years.
Dr Amarnath, Orthopaedic Surgeon and Chairman – Indian Osteoporosis Council of the IOA, said, “The development of the Indian Osteoporosis Guidelines 2025 was a rigorous and highly collaborative effort involving experts from across the country. Through multiple structured rounds of consensus, in-depth deliberations, and careful evaluation of available evidence, the panel worked to ensure that the recommendations are both scientifically sound and practical for day-to-day clinical use. Our shared objective was to create guidelines that truly assist doctors in delivering consistent and effective osteoporosis care within the Indian healthcare setting.”
Dr Srinivas Kambhampati, Orthopaedic Surgeon and Editor-in-Chief, Indian Journal of Orthopaedics, stated, “Osteoporosis continues to pose a significant and growing challenge in India, particularly with an ageing population and rising fracture risk. These guidelines provide clinicians with a clear, evidence-based, and context-specific framework that supports informed decision-making in screening, diagnosis, and management. Their publication in the Indian Journal of Orthopaedics reflects both the academic rigour of the process and their value as a long-term reference for practising doctors and researchers alike.”
With a legacy spanning more than seven decades, Pharmed continues to focus on evidence-based speciality healthcare solutions aimed at improving patient outcomes and quality of life. Its association with the guidelines reflects its long-standing commitment to advancing bone and joint health under the guiding philosophy of ‘making bones and joints the heart of our profession.’
Dr Jayanta Jana, Senior Executive Vice President – Medical, Regulatory Affairs, and Business Alliances, said, “At Pharmed, we believe that meaningful progress in bone health begins with strong scientific foundations. By supporting the Indian Osteoporosis Council for the release of the Indian Osteoporosis Guidelines 2025, we reaffirm our commitment to evidence-based care, preventive healthcare strategies, and long-term engagement with the medical fraternity.”
